Iron deficiency anemia

Dr. Robert McCabe is conducting a research study that compares an investigational oral iron medication (ferric maltol) versus traditional intravenous (IVI, FCM) in the treatment and maintenance of iron deficiency anaemia (IDA) in subjects with Irritable Bowel Disease (IBD, ulcerative colitis or Crohn's disease) in whom other oral iron therapies have failed or are not considered suitable.

This investigational oral iron medication has recently received marketing authorization in Europe, however is not yet approved by the Federal Drug Administration (FDA) in the United States of America (USA).

Previous studies have shown that the investigational oral medication is well tolerated and that it increases and stabilizes iron levels as well as traditional intravenous iron does. This study lasts up to 56 weeks and up to 7 visits and a telephone call. Subjects who are qualified and enrolled will be compensated for travel.

For more information or to see if you qualify, contact:

Minnesota Gastroenterology, P.A.